STING1 and Autoimmunity: Currently, most available STING agonists must be administered intratumorally due to bioavailability limitations associated with systemic administration and poor metabolic stability.64–67 In addition, systemic delivery and activation of STING can result in severe adverse side effects including autoimmunity and off-target inflammatory response.